1-[(2R)-2,3-dihydroxypropyl]-N-[2-(4-ethyl-2-fluoroanilino)-3,4-difluoro-6-methoxyphenyl]cyclopropane-1-sulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(2R)-2,3-dihydroxypropyl]-N-[2-(4-ethyl-2-fluoroanilino)-3,4-difluoro-6-methoxyphenyl]cyclopropane-1-sulfonamide
• 化学式: C₂₁H₂₅F₃N₂O₅S
• 分子量: 474.5
• InChiKey: IGZTYXVNIFQJLP-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• [EN] DIAGNOSTIC AND TREATMENT METHODS IN PATIENTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY<br/>[FR] MÉTHODES DE DIAGNOSTIC ET DE TRAITEMENT CHEZ DES PATIENTS AYANT OU PRÉSENTANT UN RISQUE DE DÉVELOPPER UNE RÉSISTANCE À UNE THÉRAPIE ANTICANCÉREUSE
  申请人：BROAD INST INC

  公开号：WO2013169858A1

  公开（公告）日：2013-11-14

  A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.